AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate

AnaptysBio (NASDAQ: ANAB) reported Q2 adjusted earnings per share of $(0.11), surpassing the analyst estimate of $(0.46) by 76.09%. This represents a significant improvement from losses of $(1.34) per share in the same quarter last year. The company's quarterly sales reached $27.488 million, exceeding expectations of $21.675 million by 26.82% and marking a 23.47% increase from $22.263 million in the prior year.